Benelux Morning Notes

Ahold Delhaize: Peer Kroger 4Q25 results. bpost: 4Q25/FY25 result in line, no dividend, FY26 outlook in line, assumptions optimistic. Eurocommercial Properties: Cautious guidance despite Swedish acquisition. Sligro: Feedback from group CMD. Universal Music Group: In line clean EBITDA, FCF below, US listing shelved

Basic-Fit/Preview FY25F results due 11 March/BUY

BFIT will report the FY25 results next week, 11 March while on 26 January it already published a trading update with an outlook for FY25 (excluding Clever Fit), a guidance for FY26 (including Clever Fit) and some details on Clever Fit. As such we are focussing on membership ingrowth trends in January/February/early March which we expect to be strong based on the latest Google Search trend data and the strong January trading update. We believe estimates for FY26F are still rather cautious, ie, be...

Bible 4Q25 - Semicap: growth outlook strengthens, but less than the do...

Today, we are publishing the Semicap Equipment section of our 30th Tech Infrastructure Quarterly Bible. The Tech Bible is a must-read for any tech investor, as it summarizes the quarterly earnings reports from the over 140 companies we track, providing an update on our key perspectives and convictions. In the coming weeks we will publish sections on Automotive, Hyperscale & Cloud, Telecom Equipment, PCs, Enterprise IT, and Foundry. 4Q25 semicap revenues increased 9% QoQ led by DRAM, while China...

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 03/05/2026

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 05/03/2026

HAL Trust : Boskalis FY25 results solid, and as expected guiding for w...

Dynamic Top Pick List Update March 2026: Removing Aedifica – Adding Pr...

The tariff war between US and China has eased, but with the Iran conflict and an erratic Trump, uncertainty will continue into 2027. Energy prices have gone ballistic, with gas prices doubling in Europe and has hit the cyclical stocks hard. The highly anticipated AI productivity gains also will have to transpire sooner or later or a US market correction becomes unavoidable. While the macro-economic impact has been limited so far, a prolonged uncertain situation will result in economic damage. We...

ASM International/Industry outperformance at a discount/BUY

ASM provided a very solid guidance for FY26. We expect this strength to continue in subsequent years as AI strength and ongoing technology transitions are key tailwinds for ASM. We expect the company to significantly outgrow its peers. We again increase our estimates, up our DCF-based target price to €950 per share (from €900) and reiterate our BUY. ASM remains on the ING Benelux Favourites list.

ASM International Upside on FY26 estimates already reflected in the va...

We provide more colour in this note on our change in TP and recommendation following ASMi FY25 results, which were good given the improved outlook. We see upside on the FY26 estimates, yet expectations for FY27 are already high and leave little room for upside, while the valuation is also above the historical average. We derive a fair value of €658 p.s. based on our FY27 diluted EPS of € 22.1 and a PE multiple of 30x. Given the downside we reduced our recommendation this morning from Accumulate ...

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 03/04/2026

D'Ieteren Sensitivity analysis on IPO rumours and earnings preview

According to Bloomberg, D'Ieteren Group has appointed Rotschild to explore strategic options for its controlling stake in Belron, people familiar with the matter said. Options considered include an IPO in the US or in the EU, with a valuation of upwards of $30bn and close to $40bn. Deliberations are preliminary and D'Ieteren could decide to keep its stake in Belron, people said. Any IPO plan would need to be agreed by the entire ownership of Belron, including CD&R, H&F, GIC and Blackrock. In thi...

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 04/03/2026

Benelux Morning Notes

Aedifica and Cofinimmo: Aedifica acquires c.80% of the shares in Cofinimmo. ASM International: 4Q25 results; strong FY26 guidance. D'Ieteren: Bloomberg reports on Belron IPO, valuation above $30bn, close to $40bn. dsm-firmenich: Symrise 2025 results and guidance. Kinepolis: Feb reassures - US box office revenue up +1% YoY, France visitors up +25% YoY. KPN: Odido data breach

Morning Notes : AED BB, ASM NA, DIE BB, IMMO BB, UCB BB

: AED BB, ASM NA, DIE BB, IMMO BB, UCB BB

UCB In-licenses preclinical bispecific TCE for B-cell autoimmune disea...

UCB and Antengene entered into an exclusive worldwide license agreement to further develop, manufacture and commercialize ATG-201, a preclinical CD19/CD3 bispecific T-cell engager. UCB will pay $ 80m in upfront and near-term milestone payments, development and commercial milestones of up to approx. $ 1.1bn, and royalties on future sales. ATG-201, being a bispecific T-cell engager, builds on UCB's autoimmune expertise, and given its potential to address a broad set of B-cell driven autoimmune dis...

ASM International N.V : The reacceleration is confirmed with advanced ...

ASM International N.V : Une ré accélération qui se confirme avec l’Adv...

Behind the bricks/ING Real Estate Monthly – February roundup

This edition marks the launch of the ING Real Estate Monthly, your one-stop snapshot of what is moving in European real estate, with a focus on the Benelux.